Company Focus
GSK
Latest GSK News
Biotechnology
UK pharma major GSK today announced that, in connection with the mRNA patent settlement reached between CureVac and BioNTech on August 7, 2025, the company will receive an upfront settlement of $370 million. 8 August 2025
Related News
Insights
Company Spotlight
A clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T) products for cancer.
Latest News & Features of interest to GSK
Biotechnology
XOMA Royalty Corporation is to buy fellow US firm LAVA Therapeutics for $1.16 to $1.24 per share in cash, plus a contingent value right (CVR), the companies announced Monday. 5 August 2025
Biotechnology
Privately-held US clinical-stage biotech Cellergy Pharma announced the appointment Christopher Cano as chief executive (CEO). 5 August 2025
Pharmaceutical
The UK’s National Health Service (NHS) and local authorities have started the rollout of world-first gonorrhoea vaccination program across the country. 5 August 2025
Biotechnology
Germany’s BioNTech has reported revenues for the second quarter 2025 of 260.8 million euros ($302 million), more than double the 128.7 million euros of the same period in 2024 and way above the consensus estimate of €137.9 million euros. 4 August 2025
Biosimilars
Biosimilars, once met with skepticism, are now an undeniable force in the global pharmaceutical market. As several blockbuster biologics lose exclusivity, biosimilars are stepping in to capture market share and drive savings for healthcare systems worldwide. 4 August 2025
Biotechnology
Philadelphia, USA-based Medicus Pharma and Boston-based biotech Helix Nanotechnologies have entered into a non-binding memorandum of understanding (MoU) in respect of their shared mutual interest in the development of thermostable infectious diseases vaccines. 4 August 2025
Biotechnology
Chinese biotech Mabgeek Biotechnology has filed to go public in Hong Kong, seeking to raise funds to support development of its pipeline of long-acting antibody therapies. The company, founded in 2016 and based in Hunan province, lists China International Capital Corporation as the sole sponsor. 4 August 2025
Pharmaceutical
Chinese biotech TenNor Therapeutics has filed to list on the main board of the Hong Kong Stock Exchange, aiming to fund late-stage development and commercialization of its pipeline of new antibacterial treatments. The Suzhou-based company is seeking to go public under Chapter 18A, a pathway for pre-revenue drugmakers. 4 August 2025
Pharmaceutical
Among last week’s news, US biotech Celcuity leapt 180% on new Phase III data for its cancer drug candidate gedatolisib. US drugmaker Madrigal Pharmaceuticals entered into a licensing deal with China’s CSPC Pharma for rights to a GLP-1 receptor inhibitor, SYH 2086, to compliment its platform in metabolic dysfunction associated steatohepatitis (MASH) – led by Rezdiffra. US President Donald Trump issued an ultimatum to a number of major pharmaceutical companies demanding that they reduce the price of their drugs in the USA. Also of note, LENZ Therapeutics received US Food and Drug Administration (FDA) approval for its VIZZ, the first aceclidine-based drug for the treatment of presbyopia in adults. 3 August 2025
Biotechnology
US mRNA specialist Moderna has announced that the UK Court of Appeal has upheld the validity of its EP'949 patent. 1 August 2025
Latest In Brief for GSK
Pharmaceutical
Johnson & Johnson has announced the submission of an extension of indication application to the European Medicines Agency (EMA) seeking approval of Akeega (niraparib/abiraterone acetate) with prednisone or prednisolone for the treatment of adults with metastatic hormone-sensitive prostate cancer (mHSPC) and homologous recombination repair (HRR) gene alterations. 3 July 2025
Latest Relevant Ones To Watch News
US specialty pharma business SERB Pharmaceuticals is acquiring Y-mAbs Therapeutics in a $412 million all-cash deal that brings the pediatric cancer drug Danyelza (naxitamab-gqgk) into its rare oncology portfolio. 6 August 2025
18 July 2025
Relevant Ones to Watch Companies
Refine Search
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze